

What will happen at the study center?

During your visits to the study center, you will have tests to see how you are responding to the study drug. These tests include but not limited to:

- Detailed examinations of your eyes
- Measurements of your body temperature, blood pressure, and heart rate
- Collection of blood and urine samples.

Why should I take part?

A clinical research study is an important step towards finding possible future treatments for nAMD.

Participants in studies like the 20170542 Study have a vital role in helping researchers understand the disease better and play an important part in ongoing efforts to improve healthcare for everyone.

Want to know more?

If you would like to learn more about the 20170542 Study, please speak to your referring physician, or contact:

Name

Study center

Address

Telephone

Email

Contacting us does not mean that you must join the study or that you will be able to participate.

Help us focus more closely on macular degeneration



The **20170542 Study** – a clinical research study for men and women with neovascular (wet) age-related macular degeneration

20170542
Study

What are clinical research studies?

Clinical research studies are carried out to:

- Find out if an investigational drug is safe to take
- Understand its side effects
- Find out if it can make you feel better

What is the 20170542 Study?

The 20170542 Study is exploring whether an investigational drug, called ABP 938, works as well as another drug called aflibercept when used to treat neovascular (or wet) age-related macular degeneration (nAMD).

Aflibercept is already approved to treat nAMD in the USA. These two drugs will be compared during this study.



Who is taking part in the 20170542 Study?

Approximately 566 participants in approximately 116 study sites around the world are expected to take part.

Can I take part?

You may be able to take part if you:

- Are 50 years of age or older
- Have been diagnosed with nAMD
- Are not currently receiving any treatment for your nAMD

Additional eligibility criteria apply.

How long will the 20170542 Study last?

The study is expected to last just over a year, during which you will be asked to visit the study site 10 times.

Which drugs will I receive?

- You will be randomized into one of two treatment groups – Group A or Group B.
- Randomization is when something is decided by chance, like drawing straws.
- One group will receive ABP 938 and one group will receive aflibercept.
- You cannot choose which group you will go into.
- Neither you nor the study team will know which drug you are taking.

How do I take the study drug?

Both study drugs will be given as injections into the “vitreous” – this is a gel-like substance that fills the inside of the eye. You will be given an anesthetic in your eye before you receive any injections.

You will receive injections every 4 weeks, which will change to 8 weeks later on in the study.

There will be no charge for any study-related treatment or care.